Targeting the immunosuppressive pathway involving the programmed death receptor-1 (PD-1) and its ligand (PD-L1) through immune checkpoint inhibition (ICI) therapy can further enhance the effectiveness of ICI in NSCLC patients who received RT [30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.